Neurotune develops medications to treat disorders of the human nervous system and is developing treatments, which modulate (tune) the connections between nerve cells and their target cells. The Company is developing a strong pipeline of drugs targeting large growing markets where there is significant unmet medical need. The indications include chronic pain and sarcopenia (age-related loss of muscle mass and strength). The latter affects 20% of of people aged 65 and 50% aged 80.

The enormous economic potential of novel drugs for the treatment of nervous system and muscle disorders lays the ground for a successful development of the Company. Neurotune’s team is determined to build a major player in providing innovative treatments for neuromuscular and nervous system disorders.

Neurotune employs a strong multi-disciplinary team of 14 people and maintains an extensive network of international collaborations. It was incorporated in January 2005 and is domiciled in Schlieren-Zurich, Switzerland.